Monday, November 2, 2009

11/3 TE-RegenMed-StemCell feed

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future.
TE-RegenMed-StemCell feed - By; Ankur Gupta Feed My Inbox

CIRM Scrutinizes Grantee Performance: The Tale of Three Terminations
November 2, 2009 at 2:10 pm

Playing the rich uncle to California stem cell researchers is unquestionably satisfying, but the folks at the state's $3 billion stem cell agency sometimes bear messages for scientists that may be less than warmly received.That's when they become regulators and stewards of the public's money. Particularly when they exercise that responsibility in a more rigorous way than is the practice at the

CSCR Withholds Names of Terminated Grantees to Avoid Unnecessary Harm
November 2, 2009 at 2:10 pm

The California Stem Cell Report is not naming the three scientists whose grants were terminated by the state's stem cell agency because doing so would unnecessarily damage their reputations.It is our understanding that none of the issues involved malfeasance. Additionally, CIRM's progress monitoring appears to be more rigorous than the standards applied by the NIH, whose practices have set

Text of Csete's Description of CIRM Grant Monitoring
November 2, 2009 at 2:10 pm

On June 17, 2009, Marie Csete, then chief scientific officer for the $3 billion California stem cell agency, briefed its directors in San Diego on how CIRM monitors the progress of its grantees. Following her presentation, one director asked her how many grants had been terminated because of lack of progress. Three, she replied.Here is the transcript of her remarks and the discussion by

CIRM as Regulator, Compliance Enforcer
November 2, 2009 at 2:05 pm

In addition to handing out $3 billion in grants to California stem cell researchers, CIRM is also a regulator, monitoring the conduct of its grantees' research to ensure they adhere to the agency's stringent ethical standards.The subject came up briefly at last week's board meeting in Los Angeles and is expected to come up again at the board meeting in December.Geoff Lomax, senior officer for

Immune therapy can protect against or treat later lymphoma
November 2, 2009 at 1:47 pm


StemEx(R) Noted as a Reliable Investigational Product of an Expanded Population of Stem Cells at Umbilical Cord Blood Symposium in Israel
November 2, 2009 at 12:47 pm


Possible origins of pancreatic cancer revealed
November 2, 2009 at 12:47 pm


NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer® NOX-A12
November 2, 2009 at 5:28 am

 

This email was sent to regenmd@gmail.comManage Your Account
Don't want to receive this feed any longer? Unsubscribe here.

No comments: